Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertension

Human Molecular Genetics

Volumn 21, Issue 14, 2012, Pages 3283-3292

  Guessous, Idris ^a,b   Dobrinas, Maria ^d   Kutalik, Zoltán ^e,g   Pruijm, Menno ^f   Ehret, Georg ^a,c   Maillard, Marc ^f   Bergmann, Sven ^e   Beckmann, Jacques S ^e,f   Cusi, Daniele ^h   Rizzi, Federica ⁱ   Cappuccio, Franco ^j   Cornuz, Jacques ^e   Paccaud, Fred ^a   Mooser, Vincent ^f,k   Gaspoz, Jean Michel ^b   Waeber, Gérard ^f   Burnier, Michel ^f   Vollenweider, Peter ^f   Eap, Chin B ^c,l   Bochud, Murielle ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b Unit of Population Epidemiology   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d Hopital de Cery   (Switzerland)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ KOS Genetic SRL   (Italy)

^j UNIVERSITY OF WARWICK   (United Kingdom)

^k GLAXOSMITHKLINE   (United States)

^l UNIVERSITY OF GENEVA   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CYTOCHROME P450 1A2;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CIGARETTE SMOKING; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; FEMALE; FOOD INTAKE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; BLOOD PRESSURE; CAFFEINE; CYTOCHROME P-450 CYP1A2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SMOKING;

EID: 84863993302     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/dds137     Document Type: Article

References (61)

1. Levy, D., Ehret, G.B., Rice, K., Verwoert, G.C., Launer, L.J., Dehghan, A., Glazer, N.L., Morrison, A.C., Johnson, A.D., Aspelund, T. et al. (2009) Genome-wide association study of blood pressure and hypertension. Nat. Genet., 41, 677-687.
2. Newton-Cheh, C., Johnson, T., Gateva, V., Tobin, M.D., Bochud, M., Coin, L., Najjar, S.S., Zhao, J.H., Heath, S.C., Eyheramendy, S. et al. (2009) Genome-wide association study identifies eight loci associated with blood pressure. Nat. Genet., 41, 666-676.
3. Zhou, S.F., Chan, E., Zhou, Z.W., Xue, C.C., Lai, X. and Duan, W. (2009) Insights into the structure, function, and regulation of human cytochrome P450 1A2. Curr. Drug Metab., 10, 713-729.
4. Laitala, V.S., Kaprio, J. and Silventoinen, K. (2008) Genetics of coffee consumption and its stability. Addiction, 103, 2054-2061.
5. Yang, A., Palmer, A.A. and de Wit, H. (2010) Genetics of caffeine consumption and responses to caffeine. Psychopharmacology (Berl.), 211, 245-257.
6. Cornelis, M.C., Monda, K.L., Yu, K., Paynter, N., Azzato, E.M., Bennett, S.N., Berndt, S.I., Boerwinkle, E., Chanock, S., Chatterjee, N. et al. (2011) Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption. PLoS Genet., 7, e1002033.
7. Djordjevic, N., Ghotbi, R., Jankovic, S. and Aklillu, E. (2010) Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2-163C.A polymorphism. Eur. J. Clin. Pharmacol., 66, 697-703.
8. Noordzij, M., Uiterwaal, C.S., Arends, L.R., Kok, F.J., Grobbee, D.E. and Geleijnse, J.M. (2005) Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. J. Hypertension, 23, 921-928.
9. James, J.E. (2004) Critical review of dietary caffeine and blood pressure: a relationship that should be taken more seriously. Psychosoc. Med., 66, 63-71.
10. Robertson, D., Wade, D., Workman, R., Woosley, R.L. and Oates, J.A. (1981) Tolerance to the humoral and hemodynamic effects of caffeine in man. J. Clin. Invest., 67, 1111-1117.
11. Klag, M.J., Wang, N.Y., Meoni, L.A., Brancati, F.L., Cooper, L.A., Liang, K.Y., Young, J.H. and Ford, D.E. (2002) Coffee intake and risk of hypertension: the Johns Hopkins precursors study. Arch Intern. Med., 162, 657-662.
12. Winkelmayer, W.C., Stampfer, M.J., Willett, W.C. and Curhan, G.C. (2005) Habitual caffeine intake and the risk of hypertension in women. JAMA, 294, 2330-2335.
13. Uiterwaal, C.S., Verschuren, W.M., Bueno-de-Mesquita, H.B., Ocke, M., Geleijnse, J.M., Boshuizen, H.C., Peeters, P.H., Feskens, E.J. and Grobbee, D.E. (2007) Coffee intake and incidence of hypertension. Am. J. Clin. Nutr., 85, 718-723.
14. Bertrand, C.A., Pomper, I., Hillman, G., Duffy, J.C. and Micheli, I. (1978) No relation between coffee and blood pressure. NEJM, 299, 315-316.
15. Lang, T., Degoulet, P., Aime, F., Fouriaud, C., Jacquinet-Salord, M.C., Laprugne, J., Main, J., Oeconomos, J., Phalente, J. and Prades, A. (1983) Relation between coffee drinking and blood pressure: analysis of 6,321 subjects in the Paris region. Am. J. Cardiol., 52, 1238-1242.
16. Stensvold, I., Tverdal, A. and Foss, O.P. (1989) The effect of coffee on blood lipids and blood pressure. Results from a Norwegian cross-sectional study, men and women, 40-42 years. J. Clin. Epidemiol, 42, 877-884.
17. Zhou, S.F., Yang, L.P., Zhou, Z.W., Liu, Y.H. and Chan, E. (2009) Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J., 11, 481-494.
18. MacLeod, S., Sinha, R., Kadlubar, F.F. and Lang, N.P. (1997) Polymorphisms of CYP1A1 and GSTM1 influence the in vivo function of CYP1A2. Mutat. Res., 376, 135-142.
19. Dobrinas, M., Cornuz, J., Oneda, B., Kohler Serra, M., Puhl, M. and Eap, C.B. (2011) Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin. Pharmacol. Ther., 90, 117-125.
20. Cornelis, M.C., Monda, K.L., Yu, K., Paynter, N., Azzato, E.M., Bennett, S.N., Berndt, S.I., Boerwinkle, E., Chanock, S., Chatterjee, N. et al. (2011) Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption. PLoS Genet., 7, e1002033.
21. Sulem, P., Gudbjartsson, D.F., Geller, F., Prokopenko, I., Feenstra, B., Aben, K.K., Franke, B., den Heijer, M., Kovacs, P., Stumvoll, M. et al. (2011) Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption. Hum. Mol. Genet., 20, 2071-2077.
22. Larsson, S.C., Mannisto, S., Virtanen, M.J., Kontto, J., Albanes, D. and Virtamo, J. (2008) Coffee and tea consumption and risk of stroke subtypes in male smokers. Stroke, 39, 1681-1687.
23. Lopez-Garcia, E., Rodriguez-Artalejo, F., Rexrode, K.M., Logroscino, G., Hu, F.B. and van Dam, R.M. (2009) Coffee consumption and risk of stroke in women. Circulation, 119, 1116-1123.
24. Larsson, S.C., Virtamo, J. and Wolk, A. (2011) Coffee consumption and risk of stroke in women. Stroke, 42, 908-912.
25. Bidel, S., Hu, G., Qiao, Q., Jousilahti, P., Antikainen, R. and Tuomilehto, J. (2006) Coffee consumption and risk of total and cardiovascular mortality among patients with type 2 diabetes. Diabetologia, 49, 2618-2626.
26. Grobbee, D.E., Rimm, E.B., Giovannucci, E., Colditz, G., Stampfer, M. and Willett, W. (1990) Coffee, caffeine, and cardiovascular disease in men. N. Eng. J. Med., 323, 1026-1032.
27. Greenberg, J.A., Dunbar, C.C., Schnoll, R., Kokolis, R., Kokolis, S. and Kassotis, J. (2007) Caffeinated beverage intake and the risk of heart disease mortality in the elderly: a prospective analysis. Am. J. Clin. Nutr., 85, 392-398.
28. Hakim, A.A., Ross, G.W., Curb, J.D., Rodriguez, B.L., Burchfiel, C.M., Sharp, D.S., Yano, K. and Abbott, R.D. (1998) Coffee consumption in hypertensive men in older middle-age and the risk of stroke: the Honolulu Heart Program. J. Clin. Epidemiol., 51, 487-494.
29. Sacco, R.L. (1997) Risk factors, outcomes, and stroke subtypes for ischemic stroke. Neurology, 49, S39-S44.
30. Gunes, A. and Dahl, M.L. (2008) Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics, 9, 625-637.
31. Ingelman-Sundberg, M., Sim, S.C., Gomez, A. and Rodriguez-Antona, C. (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther., 116, 496-526.
32. Jiang, Z., Dragin, N., Jorge-Nebert, L.F., Martin, M.V., Guengerich, F.P., Aklillu, E., Ingelman-Sundberg, M., Hammons, G.J., Lyn-Cook, B.D., Kadlubar, F.F. et al. (2006) Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet. Genomics, 16, 359-367.
33. Cauchi, S., Stucker, I., Solas, C., Laurent-Puig, P., Cenee, S., Hemon, D., Jacquet, M., Kremers, P., Beaune, P. and Massaad-Massade, L. (2001) Polymorphisms of human aryl hydrocarbon receptor (AhR) gene in a French population: relationship with CYP1A1 inducibility and lung cancer. Carcinogenesis, 22, 1819-1824.
34. Gomes, A.M., Winter, S., Klein, K., Turpeinen, M., Schaeffeler, E., Schwab, M. and Zanger, U.M. (2009) Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics, 10, 579-599.
35. Nussberger, J., Mooser, V., Maridor, G., Juillerat, L., Waeber, B. and Brunner, H.R. (1990) Caffeine-induced diuresis and atrial natriuretic peptides. J. Cardiovasc. Pharmacol., 15, 685-691.
36. Passmore, A.P., Kondowe, G.B. and Johnston, G.D. (1987) Renal and cardiovascular effects of caffeine: a dose-response study. Clin. Sci. (Lond.), 72, 749-756.
37. Biaggioni, I., Paul, S., Puckett, A. and Arzubiaga, C. (1991) Caffeine and theophylline as adenosine receptor antagonists in humans. J. Pharmacol. Exp. Ther., 258, 588-593.
38. Fredholm, B.B., Ijzerman, A.P., Jacobson, K.A., Klotz, K.N. and Linden, J. (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev., 53, 527-552.
39. Rieg, T., Steigele, H., Schnermann, J., Richter, K., Osswald, H. and Vallon, V. (2005) Requirement of intact adenosine A1 receptors for the diuretic and natriuretic action of the methylxanthines theophylline and caffeine. J. Pharmacol. Exp. Ther., 313, 403-409.
40. Knight, R.J., Bowmer, C.J. and Yates, M.S. (1993) The diuretic action of 8-cyclopentyl-1,3-dipropylxanthine, a selective A1 adenosine receptor antagonist. Br. J. Pharmacol., 109, 271-277.
41. Wilcox, C.S., Welch, W.J., Schreiner, G.F. and Belardinelli, L. (1999) Natriuretic and diuretic actions of a highly selective adenosine A1 receptor antagonist. J. Am. Soc. Nephrol., 10, 714-720.
42. Brater, D.C., Kaojarern, S. and Chennavasin, P. (1983) Pharmacodynamics of the diuretic effects of aminophylline and acetazolamide alone and combined with furosemide in normal subjects. J. Pharmacol. Exp. Ther., 227, 92-97.
43. van Buren, M., Bijlsma, J.A., Boer, P., van Rijn, H.J. and Koomans, H.A. (1993) Natriuretic and hypotensive effect of adenosine-1 blockade in essential hypertension. Hypertension, 22, 728-734.
44. Mancia, G., Laurent, S., Agabiti-Rosei, E., Ambrosioni, E., Burnier, M., Caulfield, M.J., Cifkova, R., Clement, D., Coca, A., Dominiczak, A. et al. (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press., 18, 308-347.
45. Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, J.L. Jr, Jones, D.W., Materson, B.J., Oparil, S., Wright, J.T. Jr et al. (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42, 1206-1252.
46. Goldstein, L.B., Bushnell, C.D., Adams, R.J., Appel, L.J., Braun, L.T., Chaturvedi, S., Creager, M.A., Culebras, A., Eckel, R.H., Hart, R.G. et al. (2011) Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 42, 517-584.
47. Zhou, S.F., Wang, B., Yang, L.P. and Liu, J.P. (2010) Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab. Rev., 42, 268-354.
48. Djordjevic, N., Ghotbi, R., Bertilsson, L., Jankovic, S. and Aklillu, E. (2008) Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur. J. Clin. Pharmacol., 64, 381-385.
49. Faber, M.S., Jetter, A. and Fuhr, U. (2005) Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin. Pharmacol. Toxicol., 97, 125-134.
50. Cornelis, M.C., El-Sohemy, A., Kabagambe, E.K. and Campos, H. (2006) Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA, 295, 1135-1141.
51. Bochud, M., Chiolero, A., Elston, R.C. and Paccaud, F. (2008) A cautionary note on the use of Mendelian randomization to infer causation in observational epidemiology. Int. J. Epidemiol., 37, 414-416; author reply 416-417.
52. Firmann, M., Mayor, V., Vidal, P.M., Bochud, M., Pecoud, A., Hayoz, D., Paccaud, F., Preisig, M., Song, K.S., Yuan, X. et al. (2008) The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc. Disord., 8, 6.
53. El Assaad, M.A., Topouchian, J.A., Darne, B.M. and Asmar, R.G. (2002) Validation of the Omron HEM-907 device for blood pressure measurement. Blood Press. Monit., 7, 237-241.
54. Sachse, C., Brockmoller, J., Bauer, S. and Roots, I. (1999) Functional significance of a C arrow A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol., 47, 445-449.
55. Faber, M.S. and Fuhr, U. (2004) Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin. Pharmacol. Ther., 76, 178-184.
56. Eap, C.B., Bender, S., Jaquenoud Sirot, E., Cucchia, G., Jonzier-Perey, M., Baumann, P., Allorge, D. and Broly, F. (2004) Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J. Clin. Psychopharmacol., 24, 214-219.
57. Fuhr, U. and Rost, K.L. (1994) Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics, 4, 109-116.
58. Tobin, M.D., Sheehan, N.A., Scurrah, K.J. and Burton, P.R. (2005) Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure. Stat. Med., 24, 2911-2935.
59. Bochud, M. (2008) On the use of Mendelian randomization to infer causality in observational epidemiology. Eur. Heart J., 29, 2456-2457.
60. Bochud, M. and Rousson, V. (2010) Usefulness of Mendelian randomization in observational epidemiology. Int. J. Environ. Res. Public Health, 7, 711-728.
61. Lawlor, D.A., Harbord, R.M., Sterne, J.A., Timpson, N. and Davey Smith, G. (2008) Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat. Med., 27, 1133-1163.